Article
Health Care Sciences & Services
Shihan Wang, Tao Yuan, Shuoning Song, Yanbei Duo, Tianyi Zhao, Junxiang Gao, Yong Fu, Yingyue Dong, Weigang Zhao
Summary: This study aimed to explore the medium- and long-term effects of dapagliflozin on serum uric acid level in patients with type 2 diabetes mellitus. A total of 77 patients were included and divided into two groups. The results showed that dapagliflozin combined with routine glucose-lowering drugs significantly lowered serum uric acid levels in these patients, and baseline uric acid levels were identified as an influencing factor.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Medicine, General & Internal
Seul-Gee Lee, Darae Kim, Jung-Jae Lee, Hyun-Ju Lee, Ro-Kyung Moon, Yong-Joon Lee, Seung-Jun Lee, Oh-Hyun Lee, Choongki Kim, Jaewon Oh, Chan Joo Lee, Yong-Ho Lee, Seil Park, Ok-Hee Jeon, Donghoon Choi, Geu-Ru Hong, Jung-Sun Kim
Summary: In a diabetic animal model, dapagliflozin attenuated left ventricular diastolic dysfunction and cardiac fibrosis through regulation of SGK1 signaling. It also exhibited anti-inflammatory effects and ameliorated mitochondrial disruption.
Article
Endocrinology & Metabolism
Feifei Zhou, Nannan Du, Lulin Zhou, Chenxi Wang, He Ren, Qiang Sun
Summary: This meta-analysis demonstrates that sotagliflozin has an acceptable safety profile in patients with diabetes, with adverse events including genital mycotic infection, related-to-acidosis events, diarrhea, volume depletion, and severe nocturnal hypoglycemia events. The subgroup analysis of sotagliflozin dosage is of great clinical significance for guiding the use of sotagliflozin in patients with diabetes in the future.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Christina Kohlmorgen, Stephen Gerfer, Kathrin Feldmann, Soeren Twarock, Sonja Hartwig, Stefan Lehr, Meike Klier, Irena Krueger, Carolin Helten, Petra Keul, Sabine Kahl, Amin Polzin, Margitta Elvers, Ulrich Floegel, Malte Kelm, Bodo Levkau, Michael Roden, Jens W. Fischer, Maria Grandoch
Summary: The study investigated the effect of SGLT2i dapagliflozin on platelet activation and inflammation in atherogenesis. Results showed that dapagliflozin treatment reduced atherosclerotic lesion development, circulating platelet-leucocyte aggregates, and aortic macrophage infiltration. Additionally, dapagliflozin decreased platelet activation and thrombin generation without affecting bleeding time.
Article
Medicine, General & Internal
Yasuhiro Iijima, Masafumi Nakayama, Takashi Miwa, Fumiyoshi Yakou, Hirofumi Tomiyama, Junpei Shikuma, Rokuro Ito, Akihiko Tanaka, Naoki Manda, Masato Odawara
Summary: This study examined the effects of dapagliflozin as an add-on therapy for diabetes on estimated glomerular filtration rate (eGFRcys) and urinary sodium excretion. The results showed that dapagliflozin significantly increased eGFRcys and urinary sodium excretion, as well as decreased blood pressure. These findings suggest that dapagliflozin add-on therapy may have nephroprotective effects in individuals with type 2 diabetes mellitus.
Review
Pharmacology & Pharmacy
Li Liu, Fang-Hong Shi, Hua Xu, Yue Wu, Zhi-Chun Gu, Hou-Wen Lin
Summary: Ertugliflozin is effective and well tolerated in patients with type 2 diabetes compared to placebo or other hypoglycemic agents, with the exception of an increased risk of genital mycotic infection.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Hiroyuki Igarashi, Hiroshi Uchino, Momoko Kanaguchi, Kaori Hisanaga, Genki Sato, Fukumi Yoshikawa, Masashi Furuta, Naohiro Washizawa, Shuki Usui, Masahiko Miyagi, Takahisa Hirose
Summary: This study aimed to compare the effect of carbohydrate availability with reduced oral intake or lost in urine on insulin-treated type 2 diabetes patients. The results showed that the carbohydrate-restricted diet group had a higher insulin requirement, but their energy expenditure and substrate oxidation were similar to the SGLT2i group.
DIABETOLOGY & METABOLIC SYNDROME
(2023)
Article
Cardiac & Cardiovascular Systems
Rahul Aggarwal, Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Darren K. Mcguire, Silvio E. Inzucchi, Renato D. Lopes, Michael J. Davies, Phillip Banks, Bertram Pitt, Philippe Gabriel Steg
Summary: This study assessed the efficacy of Sotagliflozin on heart failure clinical outcomes in individuals with different baseline glycosylated hemoglobin levels. The results showed that Sotagliflozin reduced heart failure outcomes, regardless of baseline HbA1c.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Endocrinology & Metabolism
Ye Seul Yang, Kyung Wan Min, Seok-O Park, Kyung-Soo Kim, Jae Myung Yu, Eun-Gyoung Hong, Sung Rae Cho, Kyu Chang Won, Yong Hyun Kim, Seungjoon Oh, Sung Hee Choi, Gwanpyo Koh, Wan Huh, Su Young Kim, Kyong Soo Park
Summary: This study aimed to evaluate and compare the efficacy and safety of enavogliflozin, a newly developed sodium-glucose cotransporter 2 inhibitor, with placebo in Korean patients with type 2 diabetes mellitus. The results showed that once-daily enavogliflozin monotherapy for 12 weeks is an effective, safe, and well-tolerated treatment for Korean patients with type 2 diabetes mellitus.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Yuta Yoshimura, Yoshitaka Hashimoto, Hiroshi Okada, Maya Takegami, Hanako Nakajima, Tomoki Miyoshi, Takashi Yoshimura, Masahiro Yamazaki, Masahide Hamaguchi, Michiaki Fukui
Summary: This study aimed to investigate the effects of dapagliflozin on skeletal muscle mass in individuals with type 1 diabetes, as well as the impact of good glycemic control on skeletal muscle mass. The findings suggest that dapagliflozin treatment may lead to loss of skeletal muscle mass in non-obese individuals and older men. However, good glycemic control during treatment may prevent the onset and progression of sarcopenia.
JOURNAL OF DIABETES INVESTIGATION
(2023)
Article
Cardiac & Cardiovascular Systems
Su Ern Yeoh, Joanna Osmanska, Mark C. Petrie, Katriona J. M. Brooksbank, Andrew L. Clark, Kieran F. Docherty, Paul W. X. Foley, Kaushik Guha, Crawford A. Halliday, Pardeep S. Jhund, Paul R. Kalra, Gemma McKinley, Ninian N. Lang, Matthew M. Y. Lee, Alex McConnachie, James J. McDermott, Elke Platz, Peter Sartipy, Alison Seed, Bethany Stanley, Robin A. P. Weir, Paul Welsh, John J. McMurray, Ross T. Campbell
Summary: This study compared the efficacy of dapagliflozin and metolazone in treating non-cardiogenic pulmonary edema in patients hospitalized for heart failure. During the 3-day treatment period, there was no significant difference in weight change between dapagliflozin and metolazone. However, patients in the dapagliflozin group received a higher cumulative dose of furosemide and experienced fewer adverse events.
EUROPEAN HEART JOURNAL
(2023)
Review
Cardiac & Cardiovascular Systems
Jing Cui, Yanfei Liu, Yiwen Li, Fengqin Xu, Yue Liu
Summary: T2DM and its complications, particularly myocardial infarction (MI), pose significant health risks globally. It is crucial to actively treat CAD in T2DM patients to reduce the risk of MI recurrence. The latest clinical evidence-based research emphasizes the relationship between T2DM and MI, highlighting the need for further investigation in this field.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
James P. Curtain, Kieran F. Docherty, Pardeep S. Jhund, Mark C. Petrie, Silvio E. Inzucchi, Lars Kober, Mikhail N. Kosiborod, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sjostrand, Scott D. Solomon, John J. McMurray
Summary: The study aimed to examine the effect of dapagliflozin on the incidence of ventricular arrhythmias and sudden death in patients with HFrEF. The analysis found that dapagliflozin reduced the risk of serious ventricular arrhythmias, cardiac arrest, or sudden death in these patients compared to placebo.
EUROPEAN HEART JOURNAL
(2021)
Article
Medicine, General & Internal
Tatsuhiko Urakami, Kei Yoshida, Junichi Suzuki
Summary: This study examined the efficacy of the SGLT2 inhibitor dapagliflozin as an adjunct-to-insulin therapy in young Japanese subjects with type 1 diabetes who were diagnosed before 15 years old, were overweight, and had inadequate control despite intensive insulin therapy.
Review
Cardiac & Cardiovascular Systems
Bo Xu, Shaoqian Li, Bo Kang, Jiecan Zhou
Summary: This article examines the clinical benefit, safety, and tolerability of the four SGLT2 inhibitors approved by the US FDA for the treatment of type 2 diabetes mellitus. SGLT2 inhibitors reduce hyperglycemia by increasing urinary glucose excretion and improving beta-cell function. Early clinical trials have shown their beneficial effects with acceptable safety and excellent tolerability.
CARDIOVASCULAR DIABETOLOGY
(2022)
